Elgemtumab
Modify Date: 2024-09-22 08:02:23
Elgemtumab structure
|
Common Name | Elgemtumab | ||
|---|---|---|---|---|
| CAS Number | 1512559-37-3 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ElgemtumabElgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential[1]. |
| Name | Elgemtumab |
|---|
| Description | Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Elgemtumab(LJM716)(i.v., 20 mg/kg,once)在 BT474 乳腺癌异种移植物的 SCID 小鼠中，可以使 pHER3 最大减少 52%，pAKT 最大减少 84 %；而在 BxPC-3 胰腺异种移植物的 SCID 小鼠中，导致 pHER3 的最大抑制为 86%，pAKT 的最大抑制为 74%[1]。 Elgemtumab(LJM716)(20 mg/kg, every other day, 35 days)在 BT474 乳腺癌异种移植物的 NSG 小鼠中，可以减缓肿瘤生长[1]。 |
| References |
| No Any Chemical & Physical Properties |